Search Within

Rachel Nicole Grisham

Formats
  1. Journal Article (80)
  2. Meeting Abstract (78)
  3. Review (9)
  4. Guidelines (3)
  5. Book Section (2)
  6. Editorial (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (175)
  2. GDMT, Medicine (175)
  3. Gynecologic Medicine Service (175)
  4. Gynecology Disease Management Team (175)
  5. Solid Tumor Oncology Division (175)
  6. Surgery (76)

More Groups

People
  1. Carol Aghajanian (87)
  2. Roisin O'Cearbhaill (68)
  3. Alexia Iasonos (63)
  4. Qin Zhou (56)
  5. Dennis Chi (52)
  6. Kara Long Roche (49)

More People

Years
  1. 2025 (13)
  2. 2024 (29)
  3. 2023 (26)
  4. 2022 (23)
  5. 2021 (12)
  6. 2020 (21)

More Years

Publications
  1. Gynecologic Oncology (49)
  2. Journal of Clinical Oncology (37)
  3. International Journal of Gynecological Cancer (28)
  4. Clinical Cancer Research (8)
  5. Cancer (7)
  6. Annals of Oncology (6)

More Publications

Publishers
  1. Elsevier Inc. (50)
  2. American Society of Clinical Oncology (42)
  3. Lippincott Williams & Wilkins (30)
  4. American Association for Cancer Research (10)
  5. Wiley Blackwell (8)
  6. Nature Publishing Group (6)

More Publishers

Results (175)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Low-grade serous carcinoma of the ovary
    Journal Article

    Grisham, R. N.
    Oncology (Norwalk) (2016)

    Fulltext@MSK | Save
  • Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer
    Journal Article

    Grisham, R. N.; Sylvester, B. E.; Won, H.; McDermott, G.; DeLair, D.; Ramirez, R.; Yao, Z.; Shen, R. L.; Dao, F.; Bogomolniy, F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Carboplatin hypersensitivity reactions (HSR) in carboplatin retreatment for recurrent ovarian cancer
    Meeting Abstract

    O'Cearbhaill, R. E.; Hyman, D. M.; Tew, W. P.; Iasonos, A.; Cangemi, N. A.; Aghajanian, C.; Bell-Mcguinn, K. M.; Makker, V.; Hensley, M. L.; Konner, J. A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician's choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
    Meeting Abstract

    Monk, B. J.; Grisham, R. N.; Marth, C.; Banerjee, S. N.; Hilpert, F.; Coleman, R. L.; Pujade-Lauraine, E.; Pignata, S.; Mirza, M. R.; Oza, A. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase Ib dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
    Meeting Abstract

    Grisham, R. N.; Gordon, M. S.; Harb, W. A.; Aghajanian, C.; McMeekin, D. S.; McKinley, K.; Anderson, L. R.; Chavira, R.; Christy-Bittel, J.; Barrett, E.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician's choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
    Meeting Abstract

    Monk, B. J.; Grisham, R. N.; Marth, C.; Banerjee, S. N.; Hilpert, F.; Coleman, R. L.; Pujade-Lauraine, E.; Plgnata, S.; Mirza, M. R.; Oza, A. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Effect of enzalutamide (Enza) on androgen receptor (AR) positive (+) ovarian cancer
    Meeting Abstract

    Grisham, R. N.; Thapi, D.; Berman, T.; de Stanchina, E.; Zhou, Q.; Iasonos, A.; Iyer, G.; Aghajanian, C.; Spriggs, D. R.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer
    Journal Article

    Meisel, J. L.; Hyman, D. M.; Garg, K.; Zhou, Q.; Dao, F.; Bisogna, M.; Gao, J.; Schultz, N. D.; Grisham, R. N.; Phillips, M.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save
  • Gynecologic malignancies
    Book Section

    Eng, J.; O'cearbhaill, R.; Litvak, A.; Grisham, R. N.; Hensley, M. L.; Smith, M.; Hyman, D. M.; Tew, W. P.; Meisel, J. L.
    In Drilon, A. E.; Postow, M. A.; Krug, L. M. (Eds.) Pocket Oncology (2014)

    Fulltext@MSK | Save
  • Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer
    Journal Article

    Grisham, R. N.; Iyer, G.; Sala, E.; Zhou, Q.; Iasonos, A.; DeLair, D.; Hyman, D. M.; Aghajanian, C.
    International Journal of Gynecological Cancer (2014)

    Fulltext@MSK | Save